QOL Medical is a specialty biopharmaceutical company dedicated to improving the quality of life for patients with rare diseases, for their families, and for the physicians and caregivers who support them.

QOL Medical is a patient-centric company founded in 2003 to focus on the acquisition and commercialization of orphan products in underserved markets. QOL Medical ensures an expanded clinical awareness and patient access for improved quality of life in the treatment of rare and orphan diseases. The Company currently markets three FDA-approved products including Sucraid^®, Ethamolin^®, and
Elliotts B^® Solution.

Explore QOL’s Family of Products www.sucraid.net www.ethamolin.net www.elliottsbsolution.com

	Sucraid® (Sacrosidase) Oral Solution is the first and only FDA-approved enzyme replacement therapy of the genetically determined sucrase deficiency which is part of congenital sucrase-isomaltase deficiency (CSID).
	Ethamolin® (Ethanolamine Oleate) Injection 5% is the only FDA-approved sclerotherapy for the treatment of bleeding esophageal varices.
	Elliotts B® Solution (Buffered intrathecal electrolyte/dextrose solution) is indicated as a diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma.